ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

707
Analysis
Health Care • China
Wuxi Biologics is a global Contract Research, Development, and Manufacturing Organization (CRDMO) offering end-to-end solutions for biologics discovery, development, and manufacturing, including complex modalities like monoclonal antibodies and antibody-drug conjugates. The company provides comprehensive services from concept to commercialization, including vaccine CRDMO services. It was founded in 2010 and is headquartered in Wuxi, China.
more
•14 Mar 2021 09:07

China Healthcare Weekly (Mar.12)

The article analyzed viewpoints of potential VBP on insulin, internationalization of domestic pharmaceutical companies, commercial health...

Logo
441 Views
Share
•07 Feb 2021 09:31

China Healthcare Weekly (Feb.5)

This article analyzed the results of theĀ 4thĀ volume-based purchase, theĀ CTLA-4 antibody drug industry, theĀ orthopedic implant device market, news...

Logo
454 Views
Share
•03 Jul 2026 10:13

Hong Kong Buybacks Weekly (Jul 3rd): Tencent, Li Auto, Xiaomi, Meituan

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
115 Views
Share
•24 Jan 2021 05:49

China Equity Strategy: Domestic Funds Rush to Deploy Capital in Hong Kong Market

China mainland funds have accelerated their capital deployment in Hong Kong market in the new year. The fund inflow to Hong Kong has exceeded RMB...

Logo
Roger Xie
602 Views
Share
•22 Dec 2020 22:03

Overweight EM Vs. EAFE; Dollar Weakness Continues

Our favorite countries remain Taiwan (TAIEX) and India (SENSEX), while Brazil (Bovespa) and South Korea (KOSPI) display improving price and RS...

Logo
423 Views
Share
x